Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes

A. Crinò, M. G. Cavallo, S. Corbi, C. A. Mesturino, F. Ferrazzoli, G. Coppolino, C. Bizzarri, M. Cervoni, L. Monetini, P. Pozzilli, N. Visalli, R. Buzzetti, C. Parravano, S. Romeo, A. Perciaccante, M. C. Matteoli, S. Spera, C. Teodonio, C. Suraci, G. MultariN. Sulli, A. Cantagallo, G. De Mattia, M. R. Cassone Faldetta, M. L. Manca Bitti, G. Marietti, D. Pitocco, G. Ghirlanda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cell mediated immune response in vitro to a number of antigens has been reported in patients with Type 1 diabetes. The aim of the present study was to develop an in vivo intradermal (delayed type hypersensitivity) skin test using antigens known to be recognized by lymphocytes of patients with Type 1 diabetes and to compare, where possible, the in vivo response to the in vitro T cell proliferation to the same antigens. The skin test was performed in the following group of patients: 55 with recent onset Type 1 diabetes; 16 patients with Type 1 diabetes of longer duration; 10 patients with autoimmune thyroid disease and 20 patients with Latent Autoimmune Diabetes in Adults (LADA). Type 1 diabetes specific antigens for the skin test included glutamic acid decarboxilase (GAD65), insulin and beta casein, whereas diabetes non specific antigens included tetanus toxoid, diphteria, proteus, tubercolin, streptococcus, and glycerol as control. A multitest device consisting of heads delivering intradermally 10 μ1 of solution containing the antigens was applied to the forearms; the specific antigens were injected in one forearm whereas the non specific antigens were injected in the other forearm. Reading of the reaction, which was considered positive in the presence of a nodule of 2 mm diameter was performed 48 h after the multitest application. The in vitro T cell response to diabetes specific antigens used in the multitest was studied using conventional proliferation assays in patients with recent onset Type 1 diabetes and in age matched normal subjects. Only recent onset Type 1 diabetes patients showed an in vivo positive response to GAD65, such response being detectable in 10 patients (18%). Two patients reacted also to beta casein and insulin, all other patient groups resulted negative but 2 patients with longer duration of Type 1 diabetes. There was no apparent link between the in vivo skin test and in vitro T cell proliferation to GAD65. We conclude that in vivo cell mediated immune reaction to GAD65, insulin and beta casein can be visualized in a minority of patients with recent onset Type 1 diabetes. Further studies are required to determine specificity and whether altering the dose can improve the sensitivity of the test.

Original languageEnglish
Pages (from-to)382-386
Number of pages5
JournalClinical and Experimental Immunology
Volume123
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Intradermal Tests
Skin Tests
Type 1 Diabetes Mellitus
Antigens
Caseins
Forearm
Insulin
T-Lymphocytes
Cell Proliferation
Proteus
Tetanus Toxoid
Thyroid Diseases
Delayed Hypersensitivity
Streptococcus
Glycerol
Autoimmune Diseases

Keywords

  • Beta casein
  • GAD65
  • Insulin
  • Skin test
  • T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology

Cite this

Crinò, A., Cavallo, M. G., Corbi, S., Mesturino, C. A., Ferrazzoli, F., Coppolino, G., ... Ghirlanda, G. (2001). Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes. Clinical and Experimental Immunology, 123(3), 382-386. https://doi.org/10.1046/j.1365-2249.2001.01480.x

Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes. / Crinò, A.; Cavallo, M. G.; Corbi, S.; Mesturino, C. A.; Ferrazzoli, F.; Coppolino, G.; Bizzarri, C.; Cervoni, M.; Monetini, L.; Pozzilli, P.; Visalli, N.; Buzzetti, R.; Parravano, C.; Romeo, S.; Perciaccante, A.; Matteoli, M. C.; Spera, S.; Teodonio, C.; Suraci, C.; Multari, G.; Sulli, N.; Cantagallo, A.; De Mattia, G.; Cassone Faldetta, M. R.; Manca Bitti, M. L.; Marietti, G.; Pitocco, D.; Ghirlanda, G.

In: Clinical and Experimental Immunology, Vol. 123, No. 3, 2001, p. 382-386.

Research output: Contribution to journalArticle

Crinò, A, Cavallo, MG, Corbi, S, Mesturino, CA, Ferrazzoli, F, Coppolino, G, Bizzarri, C, Cervoni, M, Monetini, L, Pozzilli, P, Visalli, N, Buzzetti, R, Parravano, C, Romeo, S, Perciaccante, A, Matteoli, MC, Spera, S, Teodonio, C, Suraci, C, Multari, G, Sulli, N, Cantagallo, A, De Mattia, G, Cassone Faldetta, MR, Manca Bitti, ML, Marietti, G, Pitocco, D & Ghirlanda, G 2001, 'Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes', Clinical and Experimental Immunology, vol. 123, no. 3, pp. 382-386. https://doi.org/10.1046/j.1365-2249.2001.01480.x
Crinò, A. ; Cavallo, M. G. ; Corbi, S. ; Mesturino, C. A. ; Ferrazzoli, F. ; Coppolino, G. ; Bizzarri, C. ; Cervoni, M. ; Monetini, L. ; Pozzilli, P. ; Visalli, N. ; Buzzetti, R. ; Parravano, C. ; Romeo, S. ; Perciaccante, A. ; Matteoli, M. C. ; Spera, S. ; Teodonio, C. ; Suraci, C. ; Multari, G. ; Sulli, N. ; Cantagallo, A. ; De Mattia, G. ; Cassone Faldetta, M. R. ; Manca Bitti, M. L. ; Marietti, G. ; Pitocco, D. ; Ghirlanda, G. / Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes. In: Clinical and Experimental Immunology. 2001 ; Vol. 123, No. 3. pp. 382-386.
@article{0f4ded6c63734d26bc3470c26d78a2e6,
title = "Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes",
abstract = "Cell mediated immune response in vitro to a number of antigens has been reported in patients with Type 1 diabetes. The aim of the present study was to develop an in vivo intradermal (delayed type hypersensitivity) skin test using antigens known to be recognized by lymphocytes of patients with Type 1 diabetes and to compare, where possible, the in vivo response to the in vitro T cell proliferation to the same antigens. The skin test was performed in the following group of patients: 55 with recent onset Type 1 diabetes; 16 patients with Type 1 diabetes of longer duration; 10 patients with autoimmune thyroid disease and 20 patients with Latent Autoimmune Diabetes in Adults (LADA). Type 1 diabetes specific antigens for the skin test included glutamic acid decarboxilase (GAD65), insulin and beta casein, whereas diabetes non specific antigens included tetanus toxoid, diphteria, proteus, tubercolin, streptococcus, and glycerol as control. A multitest device consisting of heads delivering intradermally 10 μ1 of solution containing the antigens was applied to the forearms; the specific antigens were injected in one forearm whereas the non specific antigens were injected in the other forearm. Reading of the reaction, which was considered positive in the presence of a nodule of 2 mm diameter was performed 48 h after the multitest application. The in vitro T cell response to diabetes specific antigens used in the multitest was studied using conventional proliferation assays in patients with recent onset Type 1 diabetes and in age matched normal subjects. Only recent onset Type 1 diabetes patients showed an in vivo positive response to GAD65, such response being detectable in 10 patients (18{\%}). Two patients reacted also to beta casein and insulin, all other patient groups resulted negative but 2 patients with longer duration of Type 1 diabetes. There was no apparent link between the in vivo skin test and in vitro T cell proliferation to GAD65. We conclude that in vivo cell mediated immune reaction to GAD65, insulin and beta casein can be visualized in a minority of patients with recent onset Type 1 diabetes. Further studies are required to determine specificity and whether altering the dose can improve the sensitivity of the test.",
keywords = "Beta casein, GAD65, Insulin, Skin test, T cells, Type 1 diabetes",
author = "A. Crin{\`o} and Cavallo, {M. G.} and S. Corbi and Mesturino, {C. A.} and F. Ferrazzoli and G. Coppolino and C. Bizzarri and M. Cervoni and L. Monetini and P. Pozzilli and N. Visalli and R. Buzzetti and C. Parravano and S. Romeo and A. Perciaccante and Matteoli, {M. C.} and S. Spera and C. Teodonio and C. Suraci and G. Multari and N. Sulli and A. Cantagallo and {De Mattia}, G. and {Cassone Faldetta}, {M. R.} and {Manca Bitti}, {M. L.} and G. Marietti and D. Pitocco and G. Ghirlanda",
year = "2001",
doi = "10.1046/j.1365-2249.2001.01480.x",
language = "English",
volume = "123",
pages = "382--386",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes

AU - Crinò, A.

AU - Cavallo, M. G.

AU - Corbi, S.

AU - Mesturino, C. A.

AU - Ferrazzoli, F.

AU - Coppolino, G.

AU - Bizzarri, C.

AU - Cervoni, M.

AU - Monetini, L.

AU - Pozzilli, P.

AU - Visalli, N.

AU - Buzzetti, R.

AU - Parravano, C.

AU - Romeo, S.

AU - Perciaccante, A.

AU - Matteoli, M. C.

AU - Spera, S.

AU - Teodonio, C.

AU - Suraci, C.

AU - Multari, G.

AU - Sulli, N.

AU - Cantagallo, A.

AU - De Mattia, G.

AU - Cassone Faldetta, M. R.

AU - Manca Bitti, M. L.

AU - Marietti, G.

AU - Pitocco, D.

AU - Ghirlanda, G.

PY - 2001

Y1 - 2001

N2 - Cell mediated immune response in vitro to a number of antigens has been reported in patients with Type 1 diabetes. The aim of the present study was to develop an in vivo intradermal (delayed type hypersensitivity) skin test using antigens known to be recognized by lymphocytes of patients with Type 1 diabetes and to compare, where possible, the in vivo response to the in vitro T cell proliferation to the same antigens. The skin test was performed in the following group of patients: 55 with recent onset Type 1 diabetes; 16 patients with Type 1 diabetes of longer duration; 10 patients with autoimmune thyroid disease and 20 patients with Latent Autoimmune Diabetes in Adults (LADA). Type 1 diabetes specific antigens for the skin test included glutamic acid decarboxilase (GAD65), insulin and beta casein, whereas diabetes non specific antigens included tetanus toxoid, diphteria, proteus, tubercolin, streptococcus, and glycerol as control. A multitest device consisting of heads delivering intradermally 10 μ1 of solution containing the antigens was applied to the forearms; the specific antigens were injected in one forearm whereas the non specific antigens were injected in the other forearm. Reading of the reaction, which was considered positive in the presence of a nodule of 2 mm diameter was performed 48 h after the multitest application. The in vitro T cell response to diabetes specific antigens used in the multitest was studied using conventional proliferation assays in patients with recent onset Type 1 diabetes and in age matched normal subjects. Only recent onset Type 1 diabetes patients showed an in vivo positive response to GAD65, such response being detectable in 10 patients (18%). Two patients reacted also to beta casein and insulin, all other patient groups resulted negative but 2 patients with longer duration of Type 1 diabetes. There was no apparent link between the in vivo skin test and in vitro T cell proliferation to GAD65. We conclude that in vivo cell mediated immune reaction to GAD65, insulin and beta casein can be visualized in a minority of patients with recent onset Type 1 diabetes. Further studies are required to determine specificity and whether altering the dose can improve the sensitivity of the test.

AB - Cell mediated immune response in vitro to a number of antigens has been reported in patients with Type 1 diabetes. The aim of the present study was to develop an in vivo intradermal (delayed type hypersensitivity) skin test using antigens known to be recognized by lymphocytes of patients with Type 1 diabetes and to compare, where possible, the in vivo response to the in vitro T cell proliferation to the same antigens. The skin test was performed in the following group of patients: 55 with recent onset Type 1 diabetes; 16 patients with Type 1 diabetes of longer duration; 10 patients with autoimmune thyroid disease and 20 patients with Latent Autoimmune Diabetes in Adults (LADA). Type 1 diabetes specific antigens for the skin test included glutamic acid decarboxilase (GAD65), insulin and beta casein, whereas diabetes non specific antigens included tetanus toxoid, diphteria, proteus, tubercolin, streptococcus, and glycerol as control. A multitest device consisting of heads delivering intradermally 10 μ1 of solution containing the antigens was applied to the forearms; the specific antigens were injected in one forearm whereas the non specific antigens were injected in the other forearm. Reading of the reaction, which was considered positive in the presence of a nodule of 2 mm diameter was performed 48 h after the multitest application. The in vitro T cell response to diabetes specific antigens used in the multitest was studied using conventional proliferation assays in patients with recent onset Type 1 diabetes and in age matched normal subjects. Only recent onset Type 1 diabetes patients showed an in vivo positive response to GAD65, such response being detectable in 10 patients (18%). Two patients reacted also to beta casein and insulin, all other patient groups resulted negative but 2 patients with longer duration of Type 1 diabetes. There was no apparent link between the in vivo skin test and in vitro T cell proliferation to GAD65. We conclude that in vivo cell mediated immune reaction to GAD65, insulin and beta casein can be visualized in a minority of patients with recent onset Type 1 diabetes. Further studies are required to determine specificity and whether altering the dose can improve the sensitivity of the test.

KW - Beta casein

KW - GAD65

KW - Insulin

KW - Skin test

KW - T cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0035072284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035072284&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2249.2001.01480.x

DO - 10.1046/j.1365-2249.2001.01480.x

M3 - Article

C2 - 11298123

AN - SCOPUS:0035072284

VL - 123

SP - 382

EP - 386

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -